Ernexa Therapeutics Inc. 8-K

What Happened
Ernexa Therapeutics Inc. (ERNA) filed a Form 8‑K on February 26, 2026 under Regulation FD to announce that it made an updated investor presentation available to the public. The filing attaches the presentation as Exhibit 99.1 and states it updates the version that was posted on December 11, 2025.

Key Details

• Filing date: February 26, 2026; company: Ernexa Therapeutics Inc., a Delaware corporation (ticker ERNA).
• Document attached: Exhibit 99.1 — Ernexa Therapeutics Investor Presentation (February 2026).
• The presentation replaces the prior version posted on December 11, 2025 and is incorporated by reference in the 8‑K.
• The 8‑K reports only Regulation FD disclosure and exhibits (no earnings, officer changes, mergers, or other material events were reported in this filing).

Why It Matters
This 8‑K makes Ernexa’s latest investor presentation publicly available so all investors have access to the same corporate materials at the same time (Regulation FD). Retail investors who follow ERNA should review Exhibit 99.1 for the company’s current messaging on operations, strategy, or pipeline; the 8‑K itself does not present financial results or other material corporate actions.